Loading clinical trials...
Loading clinical trials...
A Phase 3, Randomized, Double-Blinded, Double-Dummy Study Evaluating the Efficacy and Safety of Empasiprubart Versus Intravenous Immunoglobulin in Adults With Multifocal Motor Neuropathy
Conditions
Interventions
Empasiprubart
IVIG (Intravenous Immunoglobulin)
+2 more
Locations
109
United States
HonorHealth Neurology - Bob Bove Neuroscience Institute - Neurology
Scottsdale, Arizona, United States
The Neurology Group
Pomona, California, United States
Samir Macwan, M.D., Inc.
Rancho Mirage, California, United States
University of California San Francisco
San Francisco, California, United States
University of Colorado - Anschutz Cancer Pavilion (Neuro Onc Clinic)
Aurora, Colorado, United States
Yale University School of Medicine
New Haven, Connecticut, United States
Start Date
December 18, 2024
Primary Completion Date
September 1, 2026
Completion Date
December 1, 2029
Last Updated
March 13, 2026
Lead Sponsor
argenx
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions